● ImportantWorld7 outlets covering this

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

First publishedAug 2, 20:12 UTC

Last updatedAug 3, 09:36 UTC · 1m ago

1111111

7 outlets over time — hover a bar for its window & outletslast updated

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger - image 1 — 1 / 5

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger - image 2 — 1 / 5

● Story signals

How strong is this topic?

8.4/10Significanceimpact & urgency

6.4/10Source trustoutlet authority

7Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updatesBritain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.

Reported by 7 outlets — The Guardian US, CNBC Top News, Investing.com · Stock Market, Fortune, New York Post. See all sources ↓

Read the full report at The Guardian US ↗

Why it matters

7 outlets are covering this world story — one to watch as reporting develops.

In brief

What's the story?: Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updatesBritain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.
How widely is it covered?: 7 outlets, average source rating 6.4/10.
When was it last updated?: 1m ago.

Different angles across outlets

Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

Coverage card5 outlets
1Coverage
Scouting report
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
Sources5
TypeCoverage
The Guardian USAug 3, 07:08
CNBC Top NewsAug 3, 07:52
Investing.com · Stock MarketAug 2, 22:24
FortuneAug 2, 21:27
New York PostAug 2, 21:40

Related in the knowledge graph

organizationAstraZeneca organizationBMS organizationBristol-Myers Squibb organizationBusiness organizationContinue organizationPascal Soriot organizationPrinceton organizationTie-up

Sources (7)

Avg source rating 6.4/10

Processing cluster

A1A2A3B1B2B3

Share this article

X / Twitter LinkedIn WhatsApp

Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)

GPT Perplexity Gemini Claude